このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Effect of Xylitol Chewing Gum Consumption on Coagulation Parameters and Salivary Oral Microbiological Markers in Healthy Young Adults

2026年11月16日 更新者:Bezmialem Vakif University

The Effect of Xylitol Consumption on Blood Coagulation Parameters and Oral Microbiological Markers in Saliva in Healthy Young Adults

Xylitol is a natural sweetener that is widely used in chewing gum and oral care products because it helps prevent tooth decay. Some recent studies, mostly in older adults with heart disease or other health conditions, have raised questions about whether xylitol may affect blood clotting. It is not known whether regular, everyday amounts of xylitol have any effect on blood clotting in healthy young people.

This study will look at whether chewing xylitol gum every day for 4 weeks changes blood clotting tests in healthy adults aged 18 to 35 years. It will also look at whether xylitol gum changes the bacteria found in saliva.

Sixty healthy volunteers will be randomly assigned to one of two groups of 30 people each. One group will chew gum containing xylitol (2 pieces, 3 times a day, for a total of 6 grams of xylitol per day). The other group will chew gum that contains sorbitol instead of xylitol, in the same way and for the same length of time. Participants and researchers will know which gum is being used.

Blood and saliva samples will be collected at the start of the study and again after 4 weeks. The blood tests will measure platelet count, prothrombin time, activated partial thromboplastin time, fibrinogen, D-dimer, and thrombin-antithrombin complexes. The saliva samples will be used to study the types and amounts of bacteria in the mouth. Researchers will contact participants every week to ask how they are doing and to record any side effects.

調査の概要

詳細な説明

Background: Xylitol is a five-carbon sugar alcohol (polyol) that occurs naturally in small amounts in fruits and vegetables. It is widely used as a low-calorie sweetener and, because it helps prevent dental caries, it is commonly added to chewing gum, lozenges and oral care products. In recent years, observational and laboratory studies of some polyol sweeteners, notably erythritol, have suggested links with increased platelet reactivity and thrombotic events. A recent publication reported that high blood levels of xylitol were associated with cardiovascular events in older adults with existing cardiovascular risk factors, and that a single high dose of xylitol (30 g in a drink) increased platelet responsiveness in healthy volunteers over a short period. These findings cannot be directly applied to healthy young adults who use xylitol regularly in everyday amounts, and the effect of repeated daily xylitol intake on blood clotting in this group has not been studied in controlled trials. Xylitol is also known to affect cariogenic bacteria in the mouth, but studies that evaluate systemic clotting markers and the oral microbial profile together are lacking.

Objectives: The primary objective is to evaluate the effect of 4 weeks of daily xylitol chewing gum use on blood coagulation and thrombotic markers in healthy young adults. The secondary objective is to evaluate changes in oral microbiological markers (oral microbiome profile and relative abundance of bacterial species) in saliva.

Study Design: This is a single-center, randomized, open-label, parallel-group, controlled trial conducted at Bezmialem Vakıf University, Faculty of Dentistry, Department of Restorative Dentistry, with blood sampling and laboratory testing performed at the Bezmialem Vakıf University Hospital. Sixty healthy volunteers aged 18 to 35 years are randomly assigned (1:1, computer-based randomization) to a xylitol group (n = 30) or a control group (n = 30). The sample size was calculated using G*Power 3.1 (effect size d = 0.8, alpha = 0.05, power = 0.80), which gave 26 participants per group; 30 per group are enrolled to allow for dropouts. Because the two gums differ in taste and appearance, blinding is not applied.

Intervention: The xylitol group chews gum containing 1 g of xylitol per piece: 2 pieces, 3 times a day, for a total of 6 g of xylitol per day for 4 weeks. The control group chews sorbitol-containing, xylitol-free gum in the same way, with the same frequency and duration. Products are supplied in single-day packs. Participants record their daily gum use in a diary, and use below 80% is defined as non-adherence. During the study, participants must avoid other sweeteners, other chewing gum, polyol-rich products, oral care products that affect the oral flora, probiotics, and nutritional supplements, as well as medicines and herbal products that affect blood clotting.

Study Procedures: At baseline (Day 0), participants receive information, give written informed consent, and are screened by medical history and the eligibility criteria. After an overnight fast of at least 8 hours, a venous blood sample is taken at the hospital laboratory. A saliva sample is collected by a non-invasive method, with participants asked not to eat, drink or chew gum for at least 30 minutes beforehand. Participants then receive their study gum and instructions. Researchers contact participants once a week (telephone, message or in person) to check adherence, concurrent medication and any side effects such as gastrointestinal complaints, allergic reactions, or bleeding- or clotting-related symptoms. At the end of Week 4, blood and saliva sampling is repeated in the same way.

Measurements: Blood: platelet count, prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen, D-dimer, and thrombin-antithrombin (TAT) complexes. Saliva: oral microbiome profile and relative abundance of bacterial species. Saliva samples are coded, contain no personal identifiers, and only the microbial content is analyzed; human genome sequences are excluded from analysis.

Statistical Analysis: For each parameter, the change from baseline to Week 4 is calculated and compared between the xylitol and control groups. Normality is tested with the Shapiro-Wilk test. Independent-samples t-test (or Mann-Whitney U test) is used for between-group comparisons, and paired t-test (or Wilcoxon signed-rank test) for within-group comparisons. Repeated-measures ANOVA is used to assess time-by-group interaction where appropriate. Categorical variables are compared with chi-square or Fisher's exact test. Oral microbiome data are summarized by relative abundance and diversity indices (for example, Shannon index), and associations with coagulation markers are examined by correlation analysis. Results are reported with effect sizes and 95% confidence intervals. A two-sided p value below 0.05 is considered statistically significant.

Safety: Xylitol is a food-grade sweetener generally recognized as safe, and the 6 g daily dose is within commonly used consumption levels. Participants are healthy adults with no clotting disorders and no use of anticoagulant or antiplatelet medicines. Participants who develop a serious adverse event, a clinically significant abnormal laboratory result, or a condition requiring prohibited medication are withdrawn and referred for medical care. Participants may leave the study at any time without giving a reason. Personal data are stored under coded identifiers in accordance with Turkish personal data protection law and the Declaration of Helsinki.

研究の種類

介入

入学 (推定)

60

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~35年 (大人)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Healthy male or female adults aged 18 to 35 years
  • Body mass index (BMI) 18.5 to 24.9 kg/m²
  • Judged healthy by medical history and clinical evaluation, with no systemic disease (cardiovascular, metabolic, endocrine, hematologic, immune, liver or kidney)
  • No regular medication use, in particular no anticoagulant, antiplatelet, corticosteroid, immunosuppressant or hormonal medicines
  • No use of antibiotics in the last 4 weeks, and no use of antiseptic mouthwash (for example chlorhexidine) in the last 2 weeks
  • Non-smoker, with no regular alcohol or substance use
  • No active oral infection, acute periodontal disease or advanced dental pathology
  • No known allergy to xylitol, sorbitol or other chewing gum ingredients
  • Agrees not to use other chewing gum, sweeteners, oral care products or probiotics during the study
  • Able to attend follow-up contacts and to follow study instructions
  • Has read and signed the written informed consent form

Exclusion Criteria:

  • Chronic systemic disease (for example diabetes, hypertension, coronary artery disease, thyroid disease, hematologic disorder, liver or kidney failure)
  • Coagulation disorder, clotting factor deficiency, or family history of thrombosis
  • Use of anticoagulants, antiplatelets, corticosteroids, immunosuppressants or hormonal medicines, including oral contraceptives
  • Known allergy, intolerance or marked gastrointestinal sensitivity to xylitol, sorbitol, other sugar alcohols or gum ingredients
  • Pregnancy, breastfeeding, or planned pregnancy
  • Systemic antibiotic use in the last 4 weeks, or regular antiseptic mouthwash use (for example chlorhexidine, povidone-iodine) in the last 2 weeks
  • Surgery, blood transfusion, serious infection or hospital stay in the last 3 months
  • Smoking, or regular alcohol or substance use
  • Active periodontal disease, oral infection, oral mucosal lesion or marked gingival bleeding
  • Professional athletes or people who exercise very intensively
  • Wish to use other sweeteners, energy drinks, vitamins or nutritional supplements during the study
  • Psychiatric illness or cognitive impairment that prevents giving informed consent
  • Regular physician supervision or chronic medication use

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:基礎科学
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Xylitol gum

Participants chew xylitol chewing gum (1 g of xylitol per piece), 2 pieces 3 times a day, for a total of 6 g of xylitol per day for 4 weeks.

Chewing gum containing 1 g of xylitol per piece. Participants chew 2 pieces 3 times a day (6 g of xylitol per day) for 4 weeks.

アクティブコンパレータ:Sorbitol gum

Participants chew xylitol-free, sorbitol-containing chewing gum, 2 pieces 3 times a day, with the same frequency and duration as the xylitol group, for 4 weeks.

Xylitol-free chewing gum containing sorbitol. Participants chew 2 pieces 3 times a day for 4 weeks, with the same frequency and duration as the xylitol group.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change in blood coagulation parameters following xylitol consumption
時間枠:Baseline and Day 30

Changes in platelet count, prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen, D-dimer, and thrombin-antithrombin (TAT) complex levels will be evaluated

Baseline and Day 30

二次結果の測定

結果測定
メジャーの説明
時間枠
Change in relative abundance of bacterial species in saliva
時間枠:Baseline and Day 30

Change from baseline to Week 4 in the relative abundance of bacterial species in saliva samples, assessed by oral microbiome analysis

Baseline and Day 30

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年7月1日

一次修了 (推定)

2027年2月15日

研究の完了 (推定)

2027年6月1日

試験登録日

最初に提出

2026年11月16日

QC基準を満たした最初の提出物

2026年11月16日

最初の投稿 (実際)

2026年11月20日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月20日

QC基準を満たした最後の更新が送信されました

2026年11月16日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する